Applied DNA Sciences Linea COVID-19 Selective Genomic Surveillance Mutation Panel

Applied DNA Sciences has launched the Linea COVID-19 Selective Genomic Surveillance Mutation Panel (SGS Panel) to enhance the utility of next-generation sequencing resources in the US to better track SARS-CoV-2 variants of concern at the local, state, and federal levels. The research-use-only SGS Panel uses a matrix of proprietary qPCR assays that target salient mutations that characterize relevant identified variants of concern to narrow the selection of positive samples worth subjecting to NGS analysis, the Stony Brook, New York-based company said. Applied DNA Sciences will offer the SGS panel in 100 reaction kits. It is also planning to offer additional RUO services that include NGS sequencing of entire viral genomes. The firm is targeting the sequencing of 100 SARS-CoV-2 viromes per day with a capacity for twice that number.